Ceftobiprole
- Generic Name
- Ceftobiprole
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O6S2
- CAS Number
- 209467-52-7
- Unique Ingredient Identifier
- 5T97333YZK
- Background
Ceftobiprole is a cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus. It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development. Ceftobiprole is the first cephalosporin to demonstrate clinical efficacy in patients with infections due to methicillin-resistant staphylococci and, if approved by regulatory authorities, is expected to be a useful addition to the armamentarium of agents for the treatment of complicated skin infections and pneumonia.
- Indication
For the treatment of serious bacterial infections in hospitalised patients.
- Associated Conditions
- Community Acquired Pneumonia (CAP), Nosocomial Pneumonia
Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)
- Conditions
- Therapeutic Drug MonitoringSubarachnoid HemorrhageIntracerebral Hemorrhage
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2021-07-21
- Target Recruit Count
- 104
- Registration Number
- NCT04132115
- Locations
- 🇮🇹
Anesthesiology and Intensive Care Clinic - Department of Medicine - ASUIUD, Udine, Italy
🇮🇹Terapia Intensiva 1, Udine, Italy
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
- Conditions
- Staphylococcal Skin InfectionsStreptococcal Infections
- Interventions
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2012-08-28
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 12
- Registration Number
- NCT01030731
Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers
- Conditions
- Staphylococcal Skin InfectionsStreptococcal Infections
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 15
- Registration Number
- NCT01026740
A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age
- Conditions
- Staphylococcal Skin InfectionsStreptococcal Infections
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 64
- Registration Number
- NCT01026636
A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients
- Conditions
- ObesityStaphylococcal Skin InfectionsStreptococcal Infections
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-08-28
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 25
- Registration Number
- NCT01026558
Effect of Ceftobiprole on Human Intestinal Microflora
- Conditions
- Antimicrobial AgentCephalosporinsDrug Resistance
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 12
- Registration Number
- NCT00965042
Pharmacokinetic Study of the Penetration of Ceftobiprole in the Bone
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 22
- Registration Number
- NCT00771524
Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 1
- Registration Number
- NCT00771719
Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 33
- Registration Number
- NCT00770978
Ceftobiprole in Hospital Acquired Pneumonia
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 106
- Registration Number
- NCT00229008
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.